Core Insights - The global healthcare private equity (PE) market is set for a strong recovery in 2025, achieving record levels in deal value and volume, with significant regional differentiation and sector evolution [1][2][3] Group 1: Market Performance - In 2025, the global healthcare PE transaction value exceeded $191 billion, marking a substantial increase from 2024 and surpassing the previous peak in 2021 [1][2] - The number of transactions reached 445, making it the second-highest annual total in history [1][2] - Exit values also surged to $156 billion, the second-highest on record, driven by an increase in large transactions, with over 40 exits exceeding $1 billion [1][2][3] Group 2: Regional Market Dynamics - Europe saw a doubling of transaction value to $59 billion, primarily due to strong growth in biopharma and healthcare services [2][3] - North America experienced a temporary pullback in the second quarter but still achieved a healthy exit value of $90 billion, supported by 26 transactions over $1 billion [2][3] - The Asia-Pacific region set a historical record for transaction value, growing over 30% compared to 2021, with significant contributions from China, Japan, and India [2][3] Group 3: Sector Trends - Biopharma continued to dominate the market, with transaction value reaching $80 billion, accounting for a significant share of overall deal volume [2][3] - Healthcare IT transactions doubled to $32 billion, driven by technology-enabled assets and a focus on analytics and workforce optimization [2][3] - Medtech showed remarkable growth, with transaction value nearly doubling to $33 billion, highlighting its emergence as a new growth engine [2][3] Group 4: Transaction Models - Sponsor-to-sponsor transactions rebounded strongly, with over 150 deals valued at more than $110 billion, indicating a robust market environment [3] - Public-to-private and carve-out transactions also gained traction, reflecting evolving investment strategies [3] - The overall increase in large transactions has led to a significant rise in average deal sizes, with more than 30 deals exceeding $1 billion [3][3] Group 5: Future Outlook - The healthcare PE market is expected to remain active in 2026, driven by high levels of dry powder and a growing number of sponsor-owned assets reaching the end of their fund lives [3] - Key questions for the future include the sustainability of European growth, the trajectory of healthcare IT, and the potential for biopharma activity to open up [3][3]

Financial Data and Key Metrics Changes - Brink's reported Q3 2025 revenue of over $1.3 billion, a 6% increase, with 5% organic growth and a 1% foreign currency tailwind [18] - Adjusted EBITDA rose 17% to $253 million, with operating profit up 24% [18] - EBITDA margins reached a record 19%, up 180 basis points year-over-year, driven by strong productivity and a favorable revenue mix [5][18] Business Line Data and Key Metrics Changes - The ATM Managed Services and Digital Retail Solutions (AMS DRS) segment saw organic growth accelerate from 16% in Q2 to 19% in Q3, now accounting for 28% of total revenue [5][11] - Cash and Valuables Management (CVM) organic growth remained consistent, but was impacted by the conversion of existing customers to AMS DRS, accounting for a 2-3 percentage point headwind [10][31] Market Data and Key Metrics Changes - The company is experiencing healthy organic growth across all geographic segments, with notable performance in North America and Latin America [11][29] - The penetration rate for ATM outsourcing remains low, indicating significant growth opportunities in both existing and new markets [13] Company Strategy and Development Direction - Brink's is focused on delivering organic growth primarily from higher-margin subscription-based services, with a strategic shift towards AMS DRS [7][10] - The company aims to maximize shareholder value through disciplined capital allocation, including share repurchase programs [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of AMS DRS, citing a healthy pipeline and strong customer conversions [27][28] - The company anticipates continued margin improvement and cash generation, with a commitment to return at least 50% of free cash flow to shareholders [9][25] Other Important Information - Free cash flow for Q3 was $175 million, a year-over-year increase of 30%, with a trailing 12-month conversion rate of 50% of adjusted EBITDA [6][18] - The net debt to EBITDA leverage ratio was reduced to 2.9 times, within the targeted range [9][22] Q&A Session Summary Question: Can you elaborate on the client traction you're seeing in both AMS and DRS? - Management noted good visibility into Q4 and the first half of next year, with strong growth in both AMS and DRS, particularly in North America and Latin America [27][28] Question: What trends are seen in the CVM business? - The CVM business experienced flat organic growth, primarily due to customer conversions to AMS DRS, which accounted for a headwind [31] Question: What internal strategies are driving growth in AMS DRS? - The company has expanded its incentive compensation plans to align more employees with AMS DRS growth, and is also exploring partnerships with channel partners to enhance sales [36][41] Question: How should investors think about North America margin potential? - Management indicated that North America margins have improved significantly, driven by a better AMS DRS mix, disciplined pricing, and operational execution, with expectations for continued margin expansion [42][46] Question: What are the midterm goals for free cash conversion from EBITDA? - The company aims for a conversion rate of 40-45%, supported by improvements in DSO and capital efficiency [49][51] Question: How does bank consolidation impact the business? - Management views bank consolidation as an opportunity for AMS solutions, providing potential cost synergies for consolidating banks [60][62]